The Dose and Duration-dependent Association between Melatonin Treatment and Overall Cognition in Alzheimer’s Dementia: A Network Meta-Analysis of Randomized Placebo-Controlled Trials

Background: While Alzheimer’s dementia (AD) has a prevalence as high as 3-32% and is associated with cognitive dysfunction and the risk of institutionalization, no efficacious and acceptable treatments can modify the course of cognitive decline in AD. Potential benefits of exogenous melatonin for co...

Descripción completa

Detalles Bibliográficos
Autores principales: Tseng, Ping-Tao, Zeng, Bing-Yan, Chen, Yen-Wen, Yang, Chun-Pai, Su, Kuan-Pin, Chen, Tien-Yu, Wu, Yi-Cheng, Tu, Yu-Kang, Lin, Pao-Yen, Carvalho, Andre F., Stubbs, Brendon, Matsuoka, Yutaka J., Li, Dian-Jeng, Liang, Chih-Sung, Hsu, Chih-Wei, Sun, Cheuk-Kwan, Cheng, Yu-Shian, Yeh, Pin-Yang, Shiue, Yow-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886806/
https://www.ncbi.nlm.nih.gov/pubmed/35450525
http://dx.doi.org/10.2174/1570159X20666220420122322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886806/
https://www.ncbi.nlm.nih.gov/pubmed/35450525
http://dx.doi.org/10.2174/1570159X20666220420122322

Ejemplares similares